Medicis Pharmaceutical Corp. (MRX) Tops Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $69.77 +2.03%
EPS Growth %: +27.1%
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +27.1%
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q4 EPS of $1.13, $0.14 better than the analyst estimate of $0.99. Revenue for the quarter came in at $572.1 million versus the consensus estimate of $508.62 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Camtek (CAMT) PT Lowered to $140 at Stifel
- Riemann Computing Publishes Technical Account of 13.1-Billion-Parameter AI Model Development
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
